NW FiPS 10II.3-R4F-1
ESi100-A
General
Cell Line |
|
| hPSCreg name | ESi100-A |
| Cite as: | ESi100-A (RRID:CVCL_A7HK) |
| Alternative name(s) |
NW FiPS 10II.3-R4F-1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKBi007-A (LB-33-5, iLB-MJD3-33f-r5) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UNEWi026-A (SF116 clone 1) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-B (SF116 clone 2) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-C (SF116 clone K) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UCLi006-A (LCMD-L302P-UCL01C2) Donor's gene variants: LMNA Donor diseases: Congenital muscular dystrophy due to LMNA mutation UKBi003-A (iLB-MJD1-32m-r9, LB-32-r9) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UKBi008-A (iLB-MJD4-34m-r1, LB-34-1) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease |
| Last update | 13th April 2023 |
| User feedback | |
Provider |
|
| Generator | Spanish Stem Cell Bank (ES) |
| Owner | Spanish Stem Cell Bank (ES) |
| Distributors | |
| Derivation country | Spain |
External Databases |
|
| BioSamples | SAMEA112641362 |
| Cellosaurus | CVCL_A7HK |
| Wikidata | Q107116600 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 40-44 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA112641311 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Characterization of 7q11.23 reciprocal aneusomy syndromes: from patients to functional pathways (and back) |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | No |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | Institution |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Clinical Research Ethics Committee of the Regenerative Medicine Center of Barcelona |
| Approval number | 347 290 1 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Clinical Research Ethics Committee of the Regenerative Medicine Center of Barcelona |
| Approval number | 347 290 1 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
Any skin fibroblast that is part of some dermis.
|
| Source cell origin | |
| Age of donor (at collection) | 40-44 |
| Collected in | 2016 |
| Passage number reprogrammed | 4 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
Yes |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | good morphology and integration and silencing of reprogramming vectors |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Unknown |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| SSEA-3 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Differentiation Potency
In vivo teratoma
In vitro directed differentiation
In vivo teratoma
In vitro directed differentiation
In vivo teratoma
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Passage number: 14
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.